PMID- 33740056 OWN - NLM STAT- MEDLINE DCOM- 20211110 LR - 20220320 IS - 1945-7197 (Electronic) IS - 0021-972X (Print) IS - 0021-972X (Linking) VI - 106 IP - 9 DP - 2021 Aug 18 TI - Plasma Concentrations of Per- and Polyfluoroalkyl Substances and Body Composition From Mid-Childhood to Early Adolescence. PG - e3760-e3770 LID - 10.1210/clinem/dgab187 [doi] AB - CONTEXT: Per- and polyfluoroalkyl substances (PFAS) may alter body composition by lowering anabolic hormones and increasing inflammation, but data are limited, particularly in adolescence when body composition is rapidly changing. OBJECTIVE: To evaluate associations of PFAS plasma concentrations in childhood with change in body composition through early adolescence. METHODS: A total of 537 children in the Boston-area Project Viva cohort participated in this study. We used multivariable linear regression and Bayesian kernel machine regression (BKMR) to examine associations of plasma concentrations of 6 PFAS, quantified by mass spectrometry, in mid-childhood (mean age, 7.9 years; 2007-2010) with change in body composition measured by dual-energy x-ray absorptiometry from mid-childhood to early adolescence (mean age, 13.1 years). RESULTS: In single-PFAS linear regression models, children with higher concentrations of perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorodecanoate (PFDA), and perfluorohexane sulfonate (PFHxS) had less accrual of lean mass (eg, -0.33 [95% CI: -0.52, -0.13] kg/m2 per doubling of PFOA). Children with higher PFOS and PFHxS had less accrual of total and truncal fat mass (eg, -0.32 [95% CI: -0.54, -0.11] kg/m2 total fat mass per doubling of PFOS), particularly subcutaneous fat mass (eg, -17.26 [95% CI -32.25, -2.27] g/m2 per doubling of PFOS). Children with higher PFDA and perfluorononanoate (PFNA) had greater accrual of visceral fat mass (eg, 0.44 [95% CI: 0.13, 0.75] g/m2 per doubling of PFDA). Results from BKMR mixture models were consistent with linear regression analyses. CONCLUSION: Early life exposure to some but not all PFAS may be associated with adverse changes in body composition. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Janis, Jaclyn A AU - Janis JA AUID- ORCID: 0000-0002-8802-5629 AD - Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USA. FAU - Rifas-Shiman, Sheryl L AU - Rifas-Shiman SL AUID- ORCID: 0000-0003-0033-920X AD - Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA. FAU - Seshasayee, Shravanthi M AU - Seshasayee SM AD - Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USA. FAU - Sagiv, Sharon AU - Sagiv S AD - Center for Environmental Research and Children's Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA. FAU - Calafat, Antonia M AU - Calafat AM AD - Centers for Disease Control and Prevention, Atlanta, GA, USA. FAU - Gold, Diane R AU - Gold DR AD - Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA. AD - Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Coull, Brent A AU - Coull BA AD - Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Rosen, Clifford J AU - Rosen CJ AD - Maine Medical Center Research Institute, Scarborough, ME, USA. FAU - Oken, Emily AU - Oken E AUID- ORCID: 0000-0003-2513-3339 AD - Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA. FAU - Fleisch, Abby F AU - Fleisch AF AUID- ORCID: 0000-0002-2789-6412 AD - Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USA. AD - Pediatric Endocrinology and Diabetes, Maine Medical Center, Portland, ME, USA. LA - eng GR - P30 ES000002/ES/NIEHS NIH HHS/United States GR - UH3 OD023286/OD/NIH HHS/United States GR - K23 ES024803/ES/NIEHS NIH HHS/United States GR - R01 ES030101/ES/NIEHS NIH HHS/United States GR - R01 ES021447/ES/NIEHS NIH HHS/United States GR - R01 HD034568/HD/NICHD NIH HHS/United States GR - R01ES030101/ES/NIEHS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism JID - 0375362 RN - 0 (Alkanesulfonic Acids) RN - 0 (Caprylates) RN - 0 (Decanoic Acids) RN - 0 (Fluorocarbons) RN - 0 (Sulfonic Acids) RN - 335-76-2 (perfluorodecanoic acid) RN - 355-46-4 (perfluorohexanesulfonic acid) RN - 947VD76D3L (perfluorooctanoic acid) RN - 9H2MAI21CL (perfluorooctane sulfonic acid) SB - IM MH - Adiposity MH - Adolescent MH - Adult MH - Alkanesulfonic Acids/blood MH - *Body Composition MH - Caprylates/blood MH - Child MH - Decanoic Acids/blood MH - Female MH - Fluorocarbons/*blood MH - Humans MH - Male MH - Sulfonic Acids/blood PMC - PMC8372642 OTO - NOTNLM OT - PFAS OT - adolescence OT - body composition OT - chemical mixtures OT - endocrine disrupting chemicals EDAT- 2021/03/20 06:00 MHDA- 2021/11/11 06:00 PMCR- 2022/03/19 CRDT- 2021/03/19 17:24 PHST- 2020/11/06 00:00 [received] PHST- 2021/03/20 06:00 [pubmed] PHST- 2021/11/11 06:00 [medline] PHST- 2021/03/19 17:24 [entrez] PHST- 2022/03/19 00:00 [pmc-release] AID - 6178948 [pii] AID - dgab187 [pii] AID - 10.1210/clinem/dgab187 [doi] PST - ppublish SO - J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3760-e3770. doi: 10.1210/clinem/dgab187.